Aprecia appoints senior VP, regulatory affairs

,

Aprecia appoints senior VP, regulatory affairs

Kathi Rinesmith, R.Ph., M.S., was named senior VP of regulatory affairs at Aprecia, the 3DP Pharmaceutical Company. Rinesmith will lead the company’s regulatory strategy, objectives, policies, and programs pertaining to the development and marketing of drug products manufactured with Aprecia’s proprietary three-dimensional printing technology platform, ZipDose Technology.

Rinesmith brings more than 30 years of experience related to the development and registration of pharmaceutical products ranging from early and late-stage product development, product approvals, and life-cycle management across several therapeutic areas. Prior to joining Aprecia, Rinesmith served as director of global regulatory affairs and global pharmacovigilance at the specialty CDMO company Adare Pharmaceuticals. Rinesmith’s regulatory and pharmacovigilance experience spans commercialized Rx, OTC, and dietary supplement products, as well as fulfillment of commercial product regulatory reporting obligations. Earlier in her career, Rinesmith held senior executive product development and regulatory roles at Camargo Pharmaceutical Services, Prasco Laboratories, Barr Labs, and Duramed Pharmaceuticals.

Kathi Rinesmith

“Kathi has comprehensive experience and qualifications that will be instrumental in advancing Aprecia’s pipeline and will be a resource for our partners to achieve regulatory and commercial success,” says Aprecia CEO Chris Gilmore. “Her leadership and strategic vision will enhance the future of Aprecia.”

“Aprecia’s 3DP drug delivery platform provides unique opportunities to improve the medication experience and make a difference in patients’ lives,” Rinesmith says. “I’m delighted to join the high performing team at Aprecia and I look forward to engaging with world-class partners who are addressing complex formulation challenges and advancing pharmaceutical science and development.”